Cargando…

Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy

Strategies to augment immunity to self/neoantigens expressed by cancers are urgently needed to expand the proportion of patients benefiting from immunotherapy, particularly for GI cancers where only a fraction of patients respond to immunotherapies. However, current vaccine strategies are limited by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flickinger, John C., Staudt, Ross E., Singh, Jagmohan, Carlson, Robert D., Barton, Joshua R., Baybutt, Trevor R., Rappaport, Jeffrey A., Zalewski, Alicja, Pattison, Amanda, Waldman, Scott A., Snook, Adam E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226178/ https://www.ncbi.nlm.nih.gov/pubmed/35739202 http://dx.doi.org/10.1038/s41541-022-00483-z

Ejemplares similares

Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity
por: Flickinger Jr, John C, et al.
Publicado: (2020)

T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C
por: Flickinger, John C., et al.
Publicado: (2022)

Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity
por: Pattison, Amanda M., et al.
Publicado: (2020)

Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy
por: Staudt, Ross E, et al.
Publicado: (2022)

Efficacy of CD46-targeting chimeric Ad5/35 adenoviral gene therapy for colorectal cancers
por: Cho, Young-Suk, et al.
Publicado: (2016)

Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients
por: Snook, Adam E., et al.
Publicado: (2019)

Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress
por: Flickinger, John C., et al.
Publicado: (2018)

Heterologous Boosting of Recombinant Adenoviral Prime Immunization With a Novel Vesicular Stomatitis Virus–vectored Tuberculosis Vaccine
por: Roediger, Elizabeth K, et al.
Publicado: (2008)

Rescue of chimeric adenoviral vectors to expand the serotype repertoire
por: Roy, Soumitra, et al.
Publicado: (2007)

Synergistic DNA-adenovirus prime-boost immunization eliminates metastatic colorectal cancer by inducing high avidity effector CD8+ T cells
por: Xiang, Bo, et al.
Publicado: (2014)

Chimpanzee adenoviral vector prime-boost regimen elicits potent immune responses against Ebola virus in mice and rhesus macaques
por: Yang, Xi, et al.
Publicado: (2019)

Oncolytic Rhabdovirus Vaccine Boosts Chimeric Anti-DEC205 Priming for Effective Cancer Immunotherapy
por: Tzelepis, Fanny, et al.
Publicado: (2020)

Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial
por: Koblin, Beryl A., et al.
Publicado: (2011)

Airway delivery of both a BCG prime and adenoviral boost drives CD4 and CD8 T cells into the lung tissue parenchyma
por: Kaveh, Daryan A., et al.
Publicado: (2020)

Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection
por: Liu, Jiaojiao, et al.
Publicado: (2021)

Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients
por: Chu, Chang, et al.
Publicado: (2023)

GUCY2C maintains intestinal LGR5(+) stem cells by opposing ER stress
por: Kraft, Crystal L., et al.
Publicado: (2017)

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review
por: Lv, Jingjing, et al.
Publicado: (2022)

Heterologous Boosting With Listeria-Based Recombinant Strains in BCG-Primed Mice Improved Protection Against Pulmonary Mycobacterial Infection
por: Liu, Si-Jing, et al.
Publicado: (2020)

APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis
por: Blomain, Erik S., et al.
Publicado: (2020)

Enhancement of Protective Efficacy through Adenoviral Vectored Vaccine Priming and Protein Boosting Strategy Encoding Triosephosphate Isomerase (SjTPI) against Schistosoma japonicum in Mice
por: Dai, Yang, et al.
Publicado: (2015)

Tu1269: IMMUNOGENICITY AND SAFETY OF HETEROLOGOUS VERSUS HOMOLOGOUS PRIME-BOOST REGIMENS WITH ADENOVIRAL VECTORED AND MRNA SARS-COV-2 VACCINE IN LIVER TRANSPLANT RECIPIENTS
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

Heterologous Prime-Boost Regimens with a Recombinant Chimpanzee Adenoviral Vector and Adjuvanted F4 Protein Elicit Polyfunctional HIV-1-Specific T-Cell Responses in Macaques
por: Lorin, Clarisse, et al.
Publicado: (2015)

Heterologous prime–boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus
por: Jung, Seo-Yeon, et al.
Publicado: (2018)

K2 Transfection System Boosts the Adenoviral Transduction of Murine Mesenchymal Stromal Cells
por: Dumitrescu, Madalina, et al.
Publicado: (2021)

Poly(I:C)/Alum Mixed Adjuvant Priming Enhances HBV Subunit Vaccine-Induced Immunity in Mice When Combined with Recombinant Adenoviral-Based HBV Vaccine Boosting
por: Chuai, Xia, et al.
Publicado: (2013)

Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy
por: Carlson, Robert D., et al.
Publicado: (2020)

An Adenoviral Vector Based Vaccine for Rhodococcus equi
por: Giles, Carla, et al.
Publicado: (2016)

Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans
por: Capone, Stefania, et al.
Publicado: (2020)

Immunogenicity and safety of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA SARS-CoV-2 vaccine in liver transplant recipients: a prospective study
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity
por: Magee, Michael S., et al.
Publicado: (2016)

The Heat-Stable Enterotoxin Receptor, Guanylyl Cyclase C, as a Pharmacological Target in Colorectal Cancer Immunotherapy: A Bench-to-Bedside Current Report
por: Baybutt, Trevor R., et al.
Publicado: (2017)

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
por: Liu, Xinxue, et al.
Publicado: (2021)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Modeling the effect of boost timing in murine irradiated sporozoite prime-boost vaccines
por: Fernandez-Arias, Cristina, et al.
Publicado: (2018)

GUCY2C-targeted chimeric antigen receptor expressing T cells extend survival in a therapeutic mouse model of metastatic colorectal cancer
por: Magee, Michael S, et al.
Publicado: (2013)

Dendritic Cell Cross-Priming Is Essential for Immune Responses to Listeria monocytogenes
por: Reinicke, Anna T., et al.
Publicado: (2009)

Ebola-GP DNA Prime rAd5-GP Boost: Influence of Prime Frequency and Prime/Boost Time Interval on the Immune Response in Non-human Primates
por: Marcus, Hadar, et al.
Publicado: (2021)

Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity
por: Tenbusch, Matthias, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_rsf2or0s2cp697mo7lvdr1p28d